SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-181680"
 

Search: id:"swepub:oai:DiVA.org:uu-181680" > Phase II study of p...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy

Hultman, Bo (author)
Uppsala universitet,Kolorektalkirurgi
Lind, Pehr (author)
Karolinska Institutet
Glimelius, Bengt (author)
Uppsala universitet,Enheten för onkologi
show more...
Sundbom, Magnus (author)
Uppsala universitet,Gastrointestinalkirurgi
Nygren, Peter (author)
Uppsala universitet,Enheten för onkologi
Haglund, Ulf (author)
Uppsala universitet,Gastrointestinalkirurgi
Mahteme, Haile (author)
Uppsala universitet,Kolorektalkirurgi
show less...
 (creator_code:org_t)
2013
2013
English.
In: Acta Oncologica. - 0284-186X .- 1651-226X. ; 52:4, s. 824-830
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BackgroundThe aim was to evaluate the feasibility and the effectiveness of neoadjuvant systemic chemotherapy followed by cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC) and early postoperative intraperitoneal chemotherapy (EPIC) in patients with peritoneal carcinomatosis (PC) from gastric cancer.Material and methodsEighteen patients (median age 57 years, range 38-74) were scheduled for three months' neoadjuvant systemic chemotherapy followed by CRS + HIPEC + EPIC.ResultsAt the time of surgery, the peritoneal tumor burden was extensive with tumor growth on the entire peritoneal cavity. Only eight patients received the entire treatment and OS was 14.3 months (range 6.1-34.3, 95% CI 6.6-20.3). Six patients had macroscopically radical (CC0) surgery and for this subgroup OS was 19.1 months (range 6.1-34.3, 95% CI 6.9-27.1). Postoperative 90-day mortality was 10% (one patient) and the perioperative grades II-IV adverse events (AE) rate was 62.5%.DiscussionNeoadjuvant chemotherapy followed by CRS + HIPEC + EPIC does not seem to be associated with prolonged OS in patients with extensive PC growth from gastric cancer unless macroscopically radical surgery is achieved. However, morbidity from this treatment is considerable and it cannot be recommended for routine care until a prospective randomized trial has been performed.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Keyword

gastric cancer
peritoneal carcinomatosis
neoadjuvant chemotherapy
cytoreductive surgery
HIPEC
Kirurgi
Surgery

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view